Alethea Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Alethea Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-11,385	Closed	-$1.27M	–	94
2017 Q3	$1.27M	Hold	11,385	–	–	1.49%	24
2017 Q2	$1.18M	Buy	11,385 +1,593	+16%	+$157K	1.34%	26
2017 Q1	$957K	Hold	9,792	–	–	1.15%	28
2016 Q4	$866K	Buy	9,792 +60	+0.6%	+$5.46K	1.09%	29
2016 Q3	$939K	Buy	9,732 +1,215	+14%	+$116K	1.3%	27
2016 Q2	$731K	Sell	8,517 -6,924	-45%	-$621K	1%	31
2016 Q1	$1.34M	Sell	15,441 -5,100	-25%	-$456K	1.49%	27
2015 Q4	$2.32M	Sell	20,541 -360	-2%	-$39.1K	2.68%	10
2015 Q3	$2.11M	Buy	+20,901	New	+$2.51M	3.21%	8

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Alethea Capital Management's IBB Position: Q4 2017 in Review

Alethea Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2017, closing a stake of 11,385 shares — an estimated $1.27M sold.

Alethea Capital Management first reported a position in IBB in Q3 2015 and held it in 9 quarters. The position peaked at $2.32M in Q4 2015. 624 funds tracked by Wall St. Rank hold IBB as of Q4 2017.

Alethea Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2017 after selling out during the quarter.
Alethea Capital Management sold 11,385 iShares Biotechnology ETF shares in Q4 2017, an estimated $1.27M.
Alethea Capital Management first reported a position in iShares Biotechnology ETF in Q3 2015 and held it in 9 quarters.
Alethea Capital Management's iShares Biotechnology ETF position peaked at $2.32M in Q4 2015.
624 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2017.

Based on Alethea Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.